General Information of the Drug (ID: M6ADRUG0202)
Name
RS-102895
Synonyms
RS102895; GTPL779; SCHEMBL9972649; CHEMBL1593104; CHEBI:93458; ZINC2563946; BCP05302; HY-18611A; AKOS030526775; CS-3487; NCGC00092306-02; AJ-40982; KB-62464; BRD-K83063356-003-01-7; 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one; 1-(4-(Trifluoromethyl)phenethyl)spiro[benzo[d][1,3]oxazine-4,4-piperidin]-2(1H)-one hydrochloride
    Click to Show/Hide
Structure
3D MOL
Formula
C21H21F3N2O2
InChI
1S/C21H21F3N2O2/c22-21(23,24)16-7-5-15(6-8-16)9-12-26-13-10-20(11-14-26)17-3-1-2-4-18(17)25-19(27)28-20/h1-8H,9-14H2,(H,25,27)
InChIKey
HIDWEYPGMLIQSN-UHFFFAOYSA-N
PubChem CID
10000456
TTD Drug ID
D0M8CJ
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
In total 1 item(s) under this drug
Crosstalk ID: M6ACROT05197
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
m6A Target Zinc finger protein 281 (ZNF281)
Epigenetic Regulator Small nucleolar RNA host gene 5 (SNHG5)
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2)
Crosstalk relationship ncRNA → m6A
Disease Breast cancer
References
Ref 1 Clinical pipeline report, company report or official report of ZAI Lab.